<DOC>
	<DOCNO>NCT01015833</DOCNO>
	<brief_summary>This randomized phase III trial study sorafenib tosylate doxorubicin hydrochloride see well work compare sorafenib tosylate alone treat patient liver cancer spread nearby tissue lymph node spread place body . Sorafenib tosylate may stop growth tumor cell block enzymes need cell growth block blood flow tumor . Drugs use chemotherapy , doxorubicin hydrochloride , work different way stop growth tumor cell , either kill cell stop dividing . It yet know whether give sorafenib tosylate together doxorubicin hydrochloride effective sorafenib tosylate alone treat liver cancer .</brief_summary>
	<brief_title>Sorafenib Tosylate With Without Doxorubicin Hydrochloride Treating Patients With Locally Advanced Metastatic Liver Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Compare overall survival ( OS ) patient treat sorafenib ( sorafenib tosylate ) doxorubicin ( doxorubicin hydrochloride ) treat sorafenib . SECONDARY OBJECTIVES : I . Compare time progression ( TTP ) patient treat sorafenib doxorubicin treat sorafenib . II . Compare progression-free-survival ( PFS ) patient treat sorafenib doxorubicin treat sorafenib . III . Compare tumor response use Response Evaluation Criteria Solid Tumors ( RECIST ) criterion patient treat sorafenib doxorubicin treat sorafenib . OUTLINE : Patients randomize 1 2 treatment arm . ARM I : Patients receive doxorubicin hydrochloride intravenously ( IV ) day 1 sorafenib tosylate orally ( PO ) daily ( QD ) twice daily ( BID ) day 1-21 . Treatment repeat every 21 day 6 course absence disease progression unacceptable toxicity . After 6 course , patient may continue receive sorafenib tosylate PO QD BID absence disease progression unacceptable toxicity . ARM II : Patients receive sorafenib tosylate PO QD BID day 1-21 . Courses repeat every 21 day absence disease progression unacceptable toxicity . After completion study treatment , patient follow every 3 month 1 year every 6 month 2 year .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Patients must pathologically cytologically proven hepatocellular carcinoma ; know mixed histology ( e.g . hepatocellular carcinoma plus cholangiocarcinoma ) fibrolamellar variant allow Patients must locally advance metastatic disease ; locally advance disease define disease deem unresectable noneligible transplant without distant metastasis Lesions must accurately measurable least one dimension ( long diameter record ) &gt; = 2 cm conventional technique &gt; = 1 cm spiral compute tomography ( CT ) scan No prior adjuvant sorafenib vRAF1 murine leukemia viral oncogene homolog ( Raf ) /vascular endothelial growth factor ( VEGF ) inhibitor ; prior adjuvant therapy allow complete &gt; 6 month prior registration document recurrence hepatocellular carcinoma ( HCC ) Patients may treat loco regional therapy provide either : A target lesion subject local therapy The target lesion ( ) within field local therapy show increase &gt; = 20 % size since last treatment Such therapy must complete least 4 week prior registration ; patient receive palliative radiation therapy bone need wait 4 week begin protocol therapy Prior therapy allow include follow : Bland embolization , radiation , radioactive microspheres , etc Chemoembolization use chemotherapy ( except , see ) Chemoembolization drugeluting bead use doxorubicin Prior therapy chemoembolization use doxorubicin non drug elute bead form NOT allow No prior systemic therapy metastatic disease No prior exposure systemic doxorubicin administer intravenously Antiviral treatment allow , however interferon therapy must stop least 4 week prior registration Allografts allow : prior history allograft , include limited liver bone marrow transplant Patients must complete major surgery &gt; = 4 week registration Concomitant treatment Rifampin St John 's Wort allow ; patient discontinue drug least 4 week prior registration No known central nervous system ( CNS ) tumor include brain metastases No clinically significant gastrointestinal bleeding event require intervention , transfusion , admission hospital within 30 day prior registration Patients history hypertension well control ( &lt; 140/90 mmHg ) regimen antihypertensive therapy Significant history cardiac disease allow : Congestive heart failure &gt; class II New York Heart Association ( NYHA ) Myocardial infarction within 6 month prior registration Serious myocardial dysfunction , define scintigraphically ( multigated acquisition scan [ MUGA ] , myocardial scintigram ) determine absolute leave ventricular ejection fraction ( LVEF ) 45 % LVEF echocardiogram ( ECHO ) normal limit individual institution No history bleed diathesis Patients receive combination antiretroviral therapy human immunodeficiency virus ( HIV ) exclude study Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Pregnancy/nursing status : woman pregnant go study ; woman breastfeed participate study Granulocytes &gt; = 1,500/uL Hemoglobin &gt; = 8.5 g/dL ; patient recent ongoing gastrointestinal bleed may transfuse reach entry hemoglobin 8.5 g/dL ; physician ensure patient require transfusion prior registration occult clinically apparent gastrointestinal bleed Platelets &gt; = 75,000/uL Creatinine = &lt; 1.5 x upper limit normal ( ULN ) ( creatinine clearance calculate &gt; = 60 cc/minute ) ChildPugh score A ; patient must meet laboratory value requirement Bilirubin = &lt; 3 mg/dL Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) = &lt; 5 x ULN Prothrombin time ( PT ) international normalize ratio ( INR ) = &lt; 1.7 ( require patient anticoagulation agent ; patient therapeutically anticoagulated agent Coumadin heparin allow participate provide prior evidence underlie abnormality parameter exists )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>